Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17573283 | 0.85 | SMN1; SMN2 (0.33) | SMN1; SMN2MAPT | |
| SCHEMBL17849528 | 0.81 | PTK2 (0.36) | KMT2AMEN1PIK3C3CYP19A1PIK3CA | |
| SCHEMBL17849529 | 0.80 | PIK3C3 (0.33) | KMT2AMEN1PIK3C3CYP19A1ALOX5AP | |
| SCHEMBL26512859 | 0.72 | KMT2A (0.39) | KMT2AMEN1CYP19A1MAPTTYK2 | |
| SCHEMBL25254240 | 0.72 | PTGS2 (0.33) | SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL30911548 | 0.70 | — | — | |
| SCHEMBL24591425 | 0.69 | SMN1; SMN2 (0.33) | SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL30911641 | 0.69 | POLB (0.39) | TYK2ALDH1A1 | |
| SCHEMBL16332421 | 0.68 | PIK3CB (0.49) | PIK3CA | |
| SCHEMBL1628347 | 0.67 | SMN1; SMN2 (0.45) | KMT2AMEN1SMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371319-B2 | Pyrrolopyridineamino derivatives as MPS1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-21 | — | — | US | disclosed |